{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:04Z","timestamp":1753891864832,"version":"3.41.2"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Oncogenic fusions of neurotrophic receptor tyrosine kinase <jats:italic>NTRK1<\/jats:italic>, <jats:italic>NTRK2<\/jats:italic>, or <jats:italic>NTRK3<\/jats:italic> genes have been found in different types of solid tumors. The treatment of patients with TRK fusion cancer with a first-generation TRK inhibitor (such as larotrectinib or entrectinib) is associated with high response rates (&amp;gt;75%), regardless of tumor histology and presence of metastases. Due to the efficacy of TRK inhibitor therapy of larotrectinib and entrectinib, it is clinically important to identify patients accurately and efficiently with TRK fusion cancer. In this retrospective study, we provide unique data on the incidence of oncogenic <jats:italic>NTRK<\/jats:italic> gene fusions in patients with brain metastases (BM) and gliomas.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>140 samples fixed and paraffin-embedded tissue (FFPE) of adult patients (59 of gliomas [17 of WHO grade II, 20 of WHO grade III and 22 glioblastomas] and 81 of brain metastasis (BM) of different primary tumors) are analyzed. Identification of <jats:italic>NTRK<\/jats:italic> gene fusions is performed using next-generation sequencing (NGS) technology using Focus RNA assay kit (Thermo Fisher Scientific).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified an <jats:italic>ETV6 (5)::NTRK3<\/jats:italic> (<jats:italic>15<\/jats:italic>) fusion event using targeted next-generation sequencing (NGS) in one of 59 glioma patient with oligodendroglioma\u2013grade II, IDH-mutated and 1p19q co-deleted at incidence of 1.69%. Five additional patients harboring <jats:italic>TMPRSS (2)::ERG (4)<\/jats:italic> were identified in pancreatic carcinoma brain metastasis (BM), prostatic carcinoma BM, endometrium BM and oligodendroglioma (grade II), IDH-mutated and 1p19q co-deleted. A <jats:italic>FGFR3 (17)::TACC3 (11)<\/jats:italic> fusion was identified in one carcinoma breast BM. Aberrant splicing to produce <jats:italic>EGFR<\/jats:italic> exons 2-7 skipping mRNA, and <jats:italic>MET<\/jats:italic> exon 14 skipping mRNA were identified in glioblastoma and pancreas carcinoma BM, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study provides data on the incidence of <jats:italic>NTRK<\/jats:italic> gene fusions in brain tumors, which could strongly support the relevance of innovative clinical trials with specific targeted therapies (larotrectinib, entrectinib) in this population of patients. <jats:italic>FGFR3 (17)::TACC3 (11)<\/jats:italic> rearrangement was detected in breast carcinoma BM with the possibility of using some specific targeted therapies and <jats:italic>TMPRSS (2)::ERG (4)<\/jats:italic> rearrangements occur in a subset of patients with, prostatic carcinoma BM, endometrium BM, and oligodendroglioma (grade II), IDH-mutated and 1p19q co-deleted, where there are yet no approved ERG-directed therapies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1382394","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T04:28:09Z","timestamp":1721190489000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The landscape of cancer-associated transcript fusions in adult brain tumors: a longitudinal assessment in 140 patients with cerebral gliomas and brain metastases"],"prefix":"10.3389","volume":"14","author":[{"given":"Philippe","family":"Metellus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Camilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Bialecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Beaufils","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Vellutini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Tomasini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manmeet S.","family":"Ahluwalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u2019Houcine","family":"Ouafik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e000023","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open"},{"key":"B3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.neuro.24.1.677","article-title":"Neurotrophins: roles in neuronal development and function","volume":"24","author":"Huang","year":"2001","journal-title":"Annu Rev Neurosci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2006.1894","article-title":"Neurotrophin-regulated signalling pathways","volume":"361","author":"Reichardt","year":"2006","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"viii5","DOI":"10.1093\/annonc\/mdz383","article-title":"Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer","author":"Amatu","year":"2019","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(01)00530-4","article-title":"Trk receptor tyrosine kinases: A bridge between cancer and neural development","volume":"169","author":"Nakagawara","year":"2001","journal-title":"Cancer Lett"},{"key":"B7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","article-title":"TRKing down an old oncogene in a new era of targeted therapy","volume":"5","author":"Vaishnavi","year":"2015","journal-title":"Cancer Discovery"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.1038\/ncomms5846","article-title":"The landscape of kinase fusions in cancer","volume":"5","author":"Stransky","year":"2014","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2019.03.008","article-title":"Detection of tumor NTRK gene fusions to identify patients who may benefit from tyrosine kinase (TRK) inhibitor therapy","volume":"21","author":"Hsiao","year":"2019","journal-title":"J Mol Diagn."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s40478-020-00980-z","article-title":"Molecular and clinicopathologic features of gliomas harboring NTRK fusions","volume":"8","author":"Torre","year":"2020","journal-title":"Acta Neuropathologica Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-022-02405-8","article-title":"The oncogenic fusion landscape in pediatric CNS neoplasms","volume":"143","author":"Roosen","year":"2022","journal-title":"Acta Neuropathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0118-3","article-title":"Molecular characterization of cancers with NTRK gene fusions","volume":"32","author":"Gatalica","year":"2019","journal-title":"Mod Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nly022","article-title":"Targetable gene fusions associate with the IDH wild-type astrocytic lineage in adult gliomas","volume":"77","author":"Ferguson","year":"2018","journal-title":"J Neuropathol. Exp Neurol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00183","article-title":"Analysis of NTRK alterations in pan-cancer adult and pediatric Malignancies: implications for NTRK-targeted therapeutics","volume":"2","author":"Okamura","year":"2018","journal-title":"JCO Precis. Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2938","article-title":"The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma","volume":"46","author":"Wu","year":"2014","journal-title":"Nat Genet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2611","article-title":"St. Jude Children\u2019s Research Hospital-Washington University Pediatric Cancer Genome Project. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas","volume":"45","author":"Zhang","year":"2013","journal-title":"Nat Genet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00573","article-title":"TRK fusion cancers in children: A clinical review and recommendations for screening","volume":"37","author":"Albert","year":"2019","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.1220834","article-title":"Transforming fusions of FGFR and TACC genes in human glioblastoma","volume":"337","author":"Singh","year":"2012","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2199","article-title":"Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma","volume":"21","author":"Di Stefano","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0032","article-title":"Genomic correlates of disease progression and treatment response in prospectively characterized gliomas","volume":"25","author":"Jonsson","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0362","article-title":"Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives","volume":"3","author":"Dieci","year":"2013","journal-title":"Cancer Discovery"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cells8070715","article-title":"Fibroblast growth factor receptor functions in glioblastoma","volume":"8","author":"Jimenez-Pascual","year":"2019","journal-title":"Cells"},{"key":"B25","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/hmg\/dds486","article-title":"Oncogenic FGFR3 gene fusions in bladder cancer","volume":"22","author":"Williams","year":"2013","journal-title":"Hum Mol Genet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz204","article-title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","volume":"30","author":"Marchi\u00f2","year":"2019","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.14806\/ej.17.1.200","article-title":"Cutadapt removes adapter sequences from high-throughput sequencing reads","volume":"17","author":"Martin","year":"2011","journal-title":"EMBnet J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200007000-00005","article-title":"Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors","volume":"24","author":"Bourgois","year":"2000","journal-title":"Am J Surg Path."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2015.10.002","article-title":"A multiplexed amplicon approach for detecting gene fusions by next-generation sequencing","volume":"18","author":"Beadling","year":"2016","journal-title":"J Mol Diagn"},{"key":"B30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/gcc.22297","article-title":"High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer","volume":"55","author":"Pfarr","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv475","article-title":"Clinical application of amplicon-based next- generation sequencing to therapeutic decision making in lung cancer","volume":"26","author":"Takeda","year":"2015","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.127","article-title":"Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance","volume":"14","author":"Schram","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nm1009-1149","article-title":"Perspectives on the development of imatinib and the future of cancer research","volume":"15","author":"Druker","year":"2009","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4\u2013ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1101\/gr.133645.111","article-title":"A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing","volume":"22","author":"Ju","year":"2012","journal-title":"Genome Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2009.10.009","article-title":"Rearrangements of NTRK1 gene in papillary thyroid carcinoma","volume":"321","author":"Greco","year":"2010","journal-title":"Mol Cell Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small- cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091940","article-title":"NTRK1 fusion in glioblastoma multiforme","volume":"9","author":"Kim","year":"2014","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3165","article-title":"TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations","volume":"26","author":"Rosen","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1030","article-title":"Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes","volume":"10","author":"Clarke","year":"2020","journal-title":"Cancer Discovery"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00089","article-title":"Benayed R.Genomic heterogeneity underlies mixed response to tropomyosin receptor kinase inhibition in recurrent glioma","volume":"2","author":"Schram","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)37053-9","article-title":"A trk nerve growth factor (NGF) receptor point mutation affecting interaction with phospholipase C-gamma 1 abolishes NGF-promoted peripherin induction but not neurite outgrowth","volume":"269","author":"Loeb","year":"1994","journal-title":"J Biol Chem"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203922","article-title":"The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium","volume":"19","author":"Russell","year":"2000","journal-title":"Oncogene"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00180-0","article-title":"Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma","volume":"2","author":"Tognon","year":"2002","journal-title":"Cancer Cell"},{"key":"B45","unstructured":"Highlights of prescribing information VITRAKVI\u00ae (Larotrectinib)2020"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15987","article-title":"Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target","volume":"8","author":"Cook","year":"2017","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy539","article-title":"Larotrectinib in adult patients with solid tumours: A multi-centre, open-label, phase I dose-escalation study","volume":"30","author":"Hong","year":"2019","journal-title":"Ann Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"B49","unstructured":"Highlights of prescribing information: ROZLYTREK (Entrectinib)2020"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discovery"},{"key":"B52","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.pharmthera.2017.02.006","article-title":"Targeting TRK family proteins in cancer","volume":"173","author":"Khotskaya","year":"2017","journal-title":"Pharmacol Ther"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.19.00011","article-title":"Larotrectinib demonstrates CNS efficacy in TRK fusion-positive solid tumors","volume":"3","author":"Rosen","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/neuonc\/noab274","article-title":"Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors","volume":"24","author":"Doz","year":"2022","journal-title":"Neuro-Oncology"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2011.01.011","article-title":"Molecular targeting of glioblastoma: drug discovery and therapies","volume":"17","author":"Bai","year":"2011","journal-title":"Trends Mol Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","year":"2008","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-15-0497","article-title":"Oncogenic gene fusion FGFR3-TACC3 Is regulated by tyrosine phosphorylation","author":"Nelson","year":"2016","journal-title":"Mol Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67144","article-title":"The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma","volume":"123","author":"Parker","year":"2013","journal-title":"J Clin Invest."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/nop\/npaa075","article-title":"FGFR3 overexpression is a useful detection tool for FGFR3 fusions and sequence variations in glioma","volume":"8","author":"Schittenhelm","year":"2020","journal-title":"Neuro-Oncology Pract"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-14-818","article-title":"Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data","volume":"14","author":"Shah","year":"2013","journal-title":"BMC Genomics"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discovery"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz057","article-title":"DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for diffuse intrinsic pontine gliomas","volume":"21","author":"Schramm","year":"2019","journal-title":"Neuro Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203409","article-title":"Oncogenic epidermal growth factor receptor mutants with tandem duplication: gene structure and effects on receptor function","volume":"19","author":"Ciesielski","year":"2000","journal-title":"Oncogene"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer Discovery"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1126\/science.1178124","article-title":"Induced chromosomal proximity and gene fusions in prostate cancer","volume":"326","author":"Mani","year":"2009","journal-title":"Science"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1382394\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T04:28:13Z","timestamp":1721190493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1382394\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":65,"alternative-id":["10.3389\/fonc.2024.1382394"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1382394","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2024,7,17]]},"article-number":"1382394"}}